SCHEMBL8254175

SCHEMBL8254175

CC1(C)c2ccccc2NC(=O)c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 1/20 0.60
▸ PDK4 Q16654 1/20 0.60
▸ ACVR1 Q04771 2/20 0.53
▸ LRRK2 Q5S007 2/20 0.53
▸ PDGFRA P16234 1/20 0.53
▸ FER P16591 1/20 0.53
▸ LTK P29376 1/20 0.53
▸ CDK8 P49336 1/20 0.53
▸ DYRK1B Q9Y463 1/20 0.53
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ GSK3B P49841 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.45
▸ CSNK1G1 Q9HCP0 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ ROS1 P08922 1/20 0.43
▸ CDK5 Q00535 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4263828 0.81 ACVR1 (0.50) PDK2PDK4ACVR1LRRK2PDGFRA
SCHEMBL2627036 0.80 PDK2 (0.59) PDK2PDK4ACVR1LRRK2PDGFRA
SCHEMBL29371027 0.79 PDK2 (0.67) PDK2PDK4MAOACYP1A2MAPT
SCHEMBL31911 0.79 PDK2 (0.67) PDK2PDK4MAOACYP1A2MAPT
SCHEMBL28706253 0.77 PDK2 (0.64) PDK2PDK4MAOACYP1A2MAPT
SCHEMBL319934 0.75 PDK2 (1.00) PDK2PDK4ALDH1A1LMNAPGR
SCHEMBL29518706 0.75 PDK2 (1.00) PDK2PDK4ALDH1A1LMNAPGR
SCHEMBL1855552 0.74 MEN1 (0.52) PDK2PDK4MAOAMAOBALDH1A1
SCHEMBL12997896 0.74 MEN1 (0.52) PDK2PDK4MAOAMAOBALDH1A1
SCHEMBL29522682 0.74 MEN1 (0.52) PDK2PDK4MAOAMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888562-B1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARM HOLDING (US) 2014-06-18 — — EP disclosed
US-8076330-B2 Dipeptidyl peptidase-IV inhibitors AMGEN INC. (US) 2011-12-13 — — US disclosed
US-8076330-B2 Dipeptidyl peptidase-IV inhibitors AMGEN INC. (US) 2011-12-13 — — US disclosed
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2011-05-12 — — US disclosed
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2011-05-12 — — US disclosed
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-01-14 — — US disclosed
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-01-14 — — US disclosed
US-7553861-B2 Dipeptidyl peptidase-IV inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-06-30 — — US disclosed
US-7553861-B2 Dipeptidyl peptidase-IV inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-06-30 — — US disclosed
WO-2006116157-A9 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS INC (US) 2007-03-01 — — WO disclosed
WO-2006116157-A2 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2006-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009961-A1 DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, DPP3, DPP7 PDK2 210/4885PDK4 43/4885ACVR1 2720/4885
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP7 PDK2 210/4885PDK4 43/4885ACVR1 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback